PELLUCID MARGINAL CORNEAL DEGENERATION
Clinical trials for PELLUCID MARGINAL CORNEAL DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new PELLUCID MARGINAL CORNEAL DEGENERATION trials appear
Sign up with your email to follow new studies for PELLUCID MARGINAL CORNEAL DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Shorter UV light may halt corneal disease just as well as longer exposure
Disease control Recruiting nowThis study tests a non-FDA-approved treatment called corneal crosslinking (CXL) for people with keratoconus and similar conditions that cause the cornea to thin and bulge, blurring vision. Participants receive vitamin B2 eye drops followed by either 18 or 24 minutes of UVA light …
Matched conditions: PELLUCID MARGINAL CORNEAL DEGENERATION
Phase: PHASE3 • Sponsor: Woolfson Eye Institute • Aim: Disease control
Last updated May 26, 2026 11:33 UTC
-
New light therapy aims to halt corneal thinning disease
Disease control Recruiting nowThis study tests a device that uses ultraviolet light and riboflavin (vitamin B2) drops to stiffen the cornea, the clear front part of the eye. It is for people aged 10 and older with keratoconus or similar conditions that cause the cornea to bulge and thin, leading to blurry vis…
Matched conditions: PELLUCID MARGINAL CORNEAL DEGENERATION
Phase: PHASE2 • Sponsor: Goodman Eye Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC